Ishita Drugs & Industries Ltd Stock Price Today (NSE: ISHITADR)
Fundamental Score
Ishita Drugs & Industries Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Ishita Drugs & Industries Ltd share price today is ₹78.51, up +0.00% on NSE/BSE as of 18 March 2026. Ishita Drugs & Industries Ltd (ISHITADR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹21.59 (Cr). The 52-week high for ISHITADR share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 22.26x, ISHITADR is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 8.40% and a debt-to-equity ratio of 0.18.
Ishita Drugs & Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Ishita Drugs & Industries Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Ishita Drugs & Share Price: A ROCE Efficiency Analysis
The pharmaceutical sector, known for its resilience due to consistent healthcare demand, faces increasing pressure to optimize capital allocation. This is because developing new drugs and bringing generics to market demands a constant stream of investment. Examining Ishita Drugs & Industries Ltd's financial health, specifically in relation to its Return on Capital Employed (ROCE), provides insight into the efficiency with which it is deploying its capital. Currently, the Ishita Drugs & share price stands at ₹72.980003, with a Price-to-Earnings (PE) ratio of 22.26 and a ROCE of 9.91%.
The 9.91% ROCE of Ishita Drugs & Industries Ltd indicates that for every ₹100 of capital employed, the company generates approximately ₹9.91 in earnings. While seemingly adequate, it's crucial to contextualize this figure within the competitive landscape. Compared to sector peers like Mankind Pharma Ltd, Smruthi Organics Ltd, and Balaxi Pharmaceuticals Ltd, a lower ROCE may suggest inefficiencies in capital deployment. For example, the perception of management quality surrounding
Mankind Pharma Ltd might translate to more effective investment decisions and higher returns, which investors then factor into their valuation of the share price.The ROCE also impacts the perceived economic moat of Ishita Drugs & Industries Ltd. A stronger, more durable moat— often built on factors like patented drugs, strong brands, or cost advantages— typically corresponds with a higher and more sustainable ROCE. A ROCE of 9.91% may not be substantial enough to create a wide moat, suggesting that the company might face greater competitive pressures. This pressure could potentially stem from generic competition or difficulties in scaling operations efficiently.
This financial analysis is part of a comprehensive 80-parameter fundamental audit of Ishita Drugs & Industries Ltd, verified by Sweta Mishra, focusing on key financial ratios and comparative analysis within the pharmaceutical sector. This information is purely observational and should not be construed as investment advice. The purpose is to understand the company's financial performance in relation to industry benchmarks and its own efficiency in capital allocation, and is not a recommendation to buy or sell stock.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Ishita Drugs & Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ISHITADR across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Attractive Valuation (P/E: 22.26 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Conservative Debt Levels (D/E: 0.18)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (17.25x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (8.40%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.91%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-26.32%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-6.12%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Limited Growth History (0.23% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-2.37 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Ishita Drugs & Industries Ltd Financial Statements
Comprehensive financial data for Ishita Drugs & Industries Ltd including income statement, balance sheet and cash flow
About ISHITADR (Ishita Drugs & Industries Ltd)
Ishita Drugs & Industries Ltd (ISHITADR) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹21.59 (Cr). Ishita Drugs & Industries Ltd has delivered a Return on Equity (ROE) of 8.40% and a ROCE of 9.91%. The debt-to-equity ratio stands at 0.18, reflecting the company's capital structure. Investors tracking ISHITADR share price can monitor key metrics including P/E ratio, promoter holding of 49.96%, and quarterly earnings growth.
Company Details
Key Leadership
ISHITADR Share Price: Frequently Asked Questions
What is the current share price of Ishita Drugs & Industries Ltd (ISHITADR)?
As of 18 Mar 2026, 10:16 am IST, Ishita Drugs & Industries Ltd share price is ₹78.51. The ISHITADR stock has a market capitalisation of ₹21.59 (Cr) on NSE/BSE.
Is ISHITADR share price Overvalued or Undervalued?
ISHITADR share price is currently trading at a P/E ratio of 22.26x, compared to the industry average of 31.77x. Based on this relative valuation, the Ishita Drugs & Industries Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ISHITADR share price?
The 52-week high of ISHITADR share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Ishita Drugs & Industries Ltd share price?
Key factors influencing ISHITADR share price include quarterly earnings growth (Sales Growth: -6.12%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Ishita Drugs & Industries Ltd a good stock for long-term investment?
Ishita Drugs & Industries Ltd shows a 5-year Profit Growth of 9.61% and an ROE of 8.40%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.18 before investing in ISHITADR shares.
How does Ishita Drugs & Industries Ltd compare with its industry peers?
Ishita Drugs & Industries Ltd competes with major peers in the Pharmaceuticals. Investors should compare ISHITADR share price P/E of 22.26x and ROE of 8.40% against the industry averages to determine competitive standing.
What is the P/E ratio of ISHITADR and what does it mean?
ISHITADR share price has a P/E ratio of 22.26x compared to the industry average of 31.77x. Investors pay ₹22 for every ₹1 of annual earnings.
How is ISHITADR performing according to Bull Run's analysis?
ISHITADR has a Bull Run fundamental score of 29.3/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ISHITADR belong to?
ISHITADR operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Ishita Drugs & Industries Ltd share price.
What is Return on Equity (ROE) and why is it important for ISHITADR?
ISHITADR has an ROE of 8.40%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Ishita Drugs & Industries Ltd generates profits from shareholders capital.
How is ISHITADR debt-to-equity ratio and what does it indicate?
ISHITADR has a debt-to-equity ratio of 0.18, which indicates conservative financing with low financial risk.
What is ISHITADR dividend yield and is it a good dividend stock?
ISHITADR offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Ishita Drugs & Industries Ltd shares.
How has ISHITADR share price grown over the past 5 years?
ISHITADR has achieved 5-year growth rates of: Sales Growth 0.23%, Profit Growth 9.61%, and EPS Growth 9.61%.
What is the promoter holding in ISHITADR and why does it matter?
Promoters hold 49.96% of ISHITADR shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Ishita Drugs & Industries Ltd.
What is ISHITADR market capitalisation category?
ISHITADR has a market capitalisation of ₹22 crores, placing it in the Small-cap category.
How volatile is ISHITADR stock?
ISHITADR has a beta of N/A. A beta > 1 suggests the Ishita Drugs & Industries Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ISHITADR operating profit margin trend?
ISHITADR has a 5-year average Operating Profit Margin (OPM) of 6.63%, indicating the company's operational efficiency.
How is ISHITADR quarterly performance?
Recent quarterly performance shows Ishita Drugs & Industries Ltd YoY Sales Growth of -6.12% and YoY Profit Growth of -26.32%.
What is the institutional holding pattern in ISHITADR?
ISHITADR has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Ishita Drugs & Industries Ltd stock.